You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

What Zejula is and how it works:

Zejula contains the active substance niraparib. Niraparib is a type of anti-cancer medicine called a PARP inhibitor. PARP inhibitors block an enzyme called poly [adenosine diphosphate-ribose] polymerase (PARP). PARP helps cells repair damaged DNA so blocking it means that the DNA of cancer cells cannot be repaired. This results in tumour cell death, helping to control the cancer. 1

What Zejula is used for:

Zejula is used in adult women for the treatment of cancer of the ovary, the fallopian tubes (part of the female reproductive system that connects the ovaries to the uterus), or the peritoneum (the membrane lining the abdomen).

Zejula is used for cancer that has:

  • responded to the first treatment with platinum-based chemotherapy, or
  • come back (recurred) after the cancer has responded to previous treatment with standard platinum-based chemotherapy. 1

Safety Information

For safety information on Zejula including information on who is suitable for a Zejula prescription, please see the Zejula patient information leaflet (PIL). This link will take you to www.medicines.ie which is a non-GSK website.

View PIL Zejula 100mg capsules

Patient Information

This information is specifically for patients that have been prescribed Zejula by a Healthcare Professional registered in Ireland.

I am a patient

View PIL Zejula 100mg film-coated tablets

References:

  1. Zejula 100mg Hard capsule Patient information: Last Accessed January 2024
  2. Zejula 100mg film-coated tablet

For further information on Zejula (niraparib) and potential side effects please see: Zejula 100mg Hard Capsule patient information and Zejula 100mg film-coated tablet patient information

Zejula is a registered trademark of the GlaxoSmithKline group of companies

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this website or in the product package leaflet. You can also report side effects directly to HPRA Pharmacovigilance on their website: www.hpra.ie. By reporting side effects, you can help provide more information on the safety of this medicine.